医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Harlan and Fluofarma Sign Strategic Collaboration Agreement

2014年07月15日 PM09:00
このエントリーをはてなブックマークに追加


 

ITINGEN, Switzerland

Harlan Laboratories, Ltd., a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, and Fluofarma, a contract research organization specializing in high content analysis, have announced a strategic partnership that will strengthen the companies’ drug discovery and translational medicine services.

Through the alliance, Harlan CRS will utilize Fluofarma’s expertise in high content analysis, biomarkers quantification and high content histology, including applications to mechanistic toxicology and prediction of toxicity.

“One of our goals is to help our customers reduce the risk of drug attrition during the development process,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “This alliance with Fluofarma enables us to strengthen our services during the early stages of development so that we can be a key partner for our customers.”

“We’re very proud of this agreement with Harlan CRS,” added Jean-Baptiste Pin, CEO of Fluofarma. “It will be a tremendous growth accelerator for Fluofarma by improving our international visibility. For us, it’s the confirmation that our high content analysis technologies and translational research skills can add value to the global drug development process.”

About Harlan Laboratories, Ltd.

Harlan Laboratories, Ltd., a subsidiary of Harlan Laboratories, Inc., provides general and specialty toxicology services through its Contract Research Services business to the global chemical, agrochemical and pharmaceutical industries. With laboratory locations in Germany, Spain, Switzerland and the UK, Harlan and its affiliates are focused on providing customers with services to optimize product development. Please visit www.harlan.com/CRS.

About Fluofarma

Fluofarma is privately held contract research organization performing and developing cell- and tissue-based assays for preclinical and clinical drug discovery by using High-Content Analysis (HCA) technologies. Based in France, Fluofarma specializes in complex drug discovery studies and proposes translational services for every step of the drug development process. In addition to its routine assays, Fluofarma develops HCA assays and models on demand. For more information, visit www.fluofarma.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140715005004/en/

CONTACT

For inquiries concerning Harlan CRS, contact:
Lea Studer, +1
308-237-5567
SCORR Marketing
lea@scorrmarketing.com
or
For
inquiries concerning Fluofarma, contact:
Jean-Baptiste Pin, +33 5
4000 3060
Fluofarma
business@fluofarma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™